Immune Design is a clinical stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design’s clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM.
Sep 8, 2017
New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response
Sep 1, 2017
Sep 28, 2017 at 10:30 AM ET